Loading...
XKRX185750
Market cap807mUSD
Dec 24, Last price  
93,300.00KRW
1D
0.65%
1Q
-18.23%
Jan 2017
-1.57%
IPO
27.98%
Name

Chong Kun Dang Pharmaceutical Corp

Chart & Performance

D1W1MN
XKRX:185750 chart
P/E
5.54
P/S
0.71
EPS
16,845.15
Div Yield, %
0.99%
Shrs. gr., 5y
0.30%
Rev. gr., 5y
11.79%
Revenues
1.67t
+12.17%
86,318,151,860544,129,759,250592,493,473,520831,985,529,730884,362,807,620956,218,889,2801,079,337,661,9901,303,005,524,3901,343,559,362,9101,488,344,728,6401,669,404,438,760
Net income
212.52b
+162.52%
4,416,973,92035,153,740,950-6,772,741,42040,946,103,41053,807,202,37042,398,534,69053,881,645,93091,632,758,68042,720,380,72080,953,361,430212,521,171,442
CFO
318.16b
+369.72%
9,959,708,95064,590,673,0807,271,990,76057,786,120,79081,672,834,51042,627,762,18077,290,596,980104,323,716,84012,903,868,10067,734,467,550318,159,906,410
Dividend
Dec 27, 20231047.618 KRW/sh
Earnings
Feb 03, 2025

Profile

Chong Kun Dang pharmaceutical Corp. engages in the manufacturing, marketing, and selling of medicines in South Korea and internationally. It provides prescription drugs for anti-hypertension, anti-hyperlipidemia, and anti-diabetics; over-the-counter drugs, such as Penzal, Prefemine, and Modcol, as well as consumer health products, such as insecticides, hair dye, etc.; and healthcare supplements with preventive benefits. The company also exports its products. Chong Kun Dang pharmaceutical Corp. was founded in 1941 and is headquartered in Seoul, South Korea.
URL
https://www.ckdpharm.com/
IPO date
Dec 06, 2013
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,669,404,439
12.17%
1,488,344,729
10.78%
1,343,559,363
3.11%
Cost of revenue
1,278,813,300
1,238,481,271
1,113,731,698
Unusual Expense (Income)
NOPBT
390,591,139
249,863,458
229,827,665
NOPBT Margin
23.40%
16.79%
17.11%
Operating Taxes
27,995,661
17,187,287
38,237,382
Tax Rate
7.17%
6.88%
16.64%
NOPAT
362,595,478
232,676,171
191,590,283
Net income
212,521,171
162.52%
80,953,361
89.50%
42,720,381
-53.38%
Dividends
(11,608,529)
(11,238,797)
(10,808,292)
Dividend yield
0.70%
1.17%
0.86%
Proceeds from repurchase of equity
(6,024,992)
(1,888,365)
(1,935,270)
BB yield
0.36%
0.20%
0.15%
Debt
Debt current
184,767,366
124,445,495
102,091,448
Long-term debt
43,061,468
112,986,798
138,432,825
Deferred revenue
1,484,754
6,438,253
5,981,975
Other long-term liabilities
38,846,152
11,650,103
2,070,097
Net debt
(178,380,083)
76,005,642
75,338,419
Cash flow
Cash from operating activities
318,159,906
67,734,468
12,903,868
CAPEX
(68,806,048)
(53,064,680)
(51,844,402)
Cash from investing activities
(171,312,904)
(65,380,323)
(90,809,305)
Cash from financing activities
(43,699,980)
(16,339,806)
85,138,949
FCF
364,848,773
174,578,552
101,924,693
Balance
Cash
365,065,295
155,861,194
187,332,600
Long term investments
41,143,622
5,565,457
(22,146,746)
Excess cash
322,738,695
87,009,415
98,007,886
Stockholders' equity
249,464,234
681,943,085
580,628,346
Invested Capital
826,265,721
759,079,384
694,206,491
ROIC
45.74%
32.02%
29.87%
ROCE
36.31%
29.53%
28.38%
EV
Common stock shares outstanding
12,723
12,249
12,440
Price
130,900.00
67.41%
78,190.40
-22.34%
100,680.07
-48.54%
Market cap
1,665,397,110
73.88%
957,783,844
-23.53%
1,252,421,007
-48.88%
EV
1,486,957,701
1,032,685,219
1,327,559,085
EBITDA
427,621,015
283,461,120
257,309,548
EV/EBITDA
3.48
3.64
5.16
Interest
9,270,969
6,846,931
4,029,894
Interest/NOPBT
2.37%
2.74%
1.75%